Ottawa-based Avivagen Inc. (TSX-Venture:VIV) is making heads turn Wednesday, by signing a partnership with CSA Animal Nutrition providing for the sales and distribution of OxC-beta Livestock by CSA in the United States.
CSA will coordinate commercial scale validation research with potential customers and fulfill a sales and distribution role with OxC-beta for poultry, swine and dairy cattle in the United States. This agreement provides Avivagen with an experienced partner with numerous established relationships throughout the United States.
It’s music to the ears of Avivagen CEO Kym Anthony, who says, "With their extensive technical experience and relationships and ability to access the US livestock and poultry markets, CSA represents a strong partner for Avivagen. The timing is good given the regulatory process in the U.S. is now completed and we look to add sales and distribution networks in new markets to significantly drive our sales."
This U.S. partnership provides Avivagen with access to 20% of the world’s Global Feed Market and encompasses poultry, swine and dairy cattle.
VIV shares galloped six cents, or 11.3%, to 59 cents, on volume of 365,000 shares.
